Landmark Phase 3 Trial Shows First Drug to Stabilize Kidney Function Decline in IgA Nephropathy Over Two Years

In a watershed moment for nephrology, a new targeted therapy has become the first to completely halt the progressive decline of kidney function in patients with IgA nephropathy (IgAN). Results from a landmark Phase 3 clinical trial demonstrate that the biologic drug Voyxact (sibeprenlimab) stabilizes the kidneys' filtration rate over two years, returning patients to the normal physiological baseline seen in healthy adults. The data, presented during a late-breaking session at the GlomCon Hawaii 2026 conference, marks a profound shift in how the medical community approaches the rare autoimmune disease. For decades, a diagnosis of IgA nephropathy carried the looming, seemingly inevitable threat of end-stage renal failure, dialysis, and the need for a kidney transplant, leaving patients and clinicians with few disease-modifying options.[1][3][5][6][7]

The Phase 3 VISIONARY trial tracked 510 adults with biopsy-confirmed IgAN who were at high risk for disease progression, making it one of the most comprehensive studies ever conducted in this patient population. Patients were randomized to receive either a monthly subcutaneous injection of sibeprenlimab or a placebo, alongside maximally tolerated standard-of-care treatments like blood pressure medications and SGLT2 inhibitors. The trial's key secondary endpoint measured the annualized slope of the estimated glomerular filtration rate (eGFR)—the definitive, gold-standard metric of how well the kidneys filter waste from the blood. Over the 24-month observation period, patients receiving the placebo experienced a steep and dangerous eGFR decline of -4.2 mL/min/1.73 m² per year, illustrating the aggressive natural trajectory of the disease.[1][2][4][6][8]

In stark contrast, patients treated with Voyxact achieved an annualized eGFR slope of +0.3 mL/min/1.73 m², a slight positive trajectory indicating that kidney function was not only preserved but entirely stabilized. This stabilization perfectly matches the normal age-related decline of less than 1 mL/min/year outlined by the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines. "Two years of eGFR stability in patients with IgAN is an incredible finding," noted Dr. John Kraus, chief medical officer at Otsuka, the pharmaceutical company behind the drug, emphasizing that the results fundamentally alter the disease's natural progression by moving beyond mere symptom management to active, long-term disease modification.[1][2][3][6]

IgA nephropathy, sometimes known as Berger's disease, typically manifests in adults between the ages of 20 and 40, striking patients in the prime of their lives and imposing a massive physical and psychological burden. The condition is driven by a complex immune system malfunction where a specific, abnormally formed protein—galactose-deficient IgA1—accumulates in the kidneys. Over time, these protein deposits trigger severe, localized inflammation, scarring the delicate glomerular filters and progressively destroying the organ's ability to clean the blood. Until recently, treatments were largely limited to broad immunosuppressants, steroids, and blood pressure drugs that only slowed the damage while exposing patients to significant systemic side effects.[3][4][5][6][7]

Voyxact represents a new class of precision medicine tailored specifically to the underlying biology of the disease. It is a humanized monoclonal antibody designed to selectively bind to and block a signaling protein known as APRIL (A Proliferation-Inducing Ligand). APRIL plays a critical role in the survival of certain B cells and the downstream production of antibodies. By neutralizing the APRIL protein, sibeprenlimab effectively cuts off the production of the pathogenic, galactose-deficient IgA1 at its biological source, preventing the harmful immune complexes from ever forming and reaching the kidneys in the first place.[1][3][4][7]

The drug's journey to this clinical milestone has been remarkably rapid, reflecting the urgent unmet need in the nephrology community. In November 2025, the U.S. Food and Drug Administration (FDA) granted Voyxact accelerated approval based on highly promising interim 9-month data from the same VISIONARY trial. That early data showed the drug reduced proteinuria—the spilling of protein into the urine, which serves as a key early marker of kidney stress and structural damage—by roughly 50% compared to placebo. However, because proteinuria is only a surrogate marker, the FDA required long-term eGFR data to definitively confirm that the drug actually preserved organ function over time.[4][5][6]

The newly released 24-month eGFR results provide that definitive proof, clearing the path for the drug's permanent integration into clinical practice. Armed with this data, Otsuka has announced it is now submitting a supplemental Biologics License Application (sBLA) to the FDA to convert the accelerated authorization into a full, traditional approval. Crucially, the profound efficacy demonstrated in the trial did not come at the cost of severe side effects. The safety profile of sibeprenlimab remained highly favorable and comparable to the placebo over the entire two-year period, with most adverse reactions reported as mild or moderate.[1][2][6]

The overall rate of adverse events was nearly identical between the two groups, hovering around 90%, with injection site reactions and mild respiratory infections being the most commonly reported issues. Furthermore, because Voyxact targets a highly specific immune pathway rather than broadly suppressing the entire immune system like traditional steroids, the rate of serious infections was actually lower in the treatment group (1.9%) compared to the placebo group (4.0%). This targeted safety profile is particularly vital for young patients who will likely need to remain on the therapy for decades to maintain their kidney health.[1][4][5]

The clinical success of sibeprenlimab arrives amid a broader renaissance in IgA nephropathy research and drug development. The treatment landscape is rapidly expanding, with several other targeted therapies advancing through late-stage clinical trials. For instance, Vera Therapeutics recently secured FDA approval for atacicept (Trutakna), a dual inhibitor that blocks both APRIL and a related cytokine called BAFF, while Novartis has gained traction with its complement pathway inhibitor Fabhalta. This wave of innovation suggests that nephrologists will soon have an arsenal of precision tools to tackle the disease from multiple biological angles, potentially opening the door to combination therapies that could drive remission rates even higher.[1][4][7]

As these precision biologics enter the market, the standard of care for IgA nephropathy is being entirely rewritten, shifting the focus from delaying failure to preserving lifelong health. Otsuka is also developing an autoinjector version of Voyxact, which would make the once-monthly at-home administration even more convenient for patients managing the chronic condition. For young adults facing a diagnosis that once guaranteed a lifetime of chronic illness, dietary restrictions, and the eventual need for organ transplantation, the ability to permanently stabilize kidney function with a targeted monthly injection offers a previously unimaginable lease on a healthy, dialysis-free life.[1][4][5][6][7]